case_images: PMC7450917_01
case_images: Magnetic resonance images of the brain (T1 axial postcontrast series) (A) before and (B) 1 month after treatment with lorlatinib, showing significant response of all metastatic brain lesions.
case_images: PO.19.00013f1.jpg
case_images: PMC7450917_01_PO.19.00013f1.jpg
case_images: f1
case_images: Lorlatinib induced a dramatic response in the brain and the systemic disease sites, evident in the first disease evaluation with imaging studies (Fig 1).
case_images: Timeline of the clinical course, highlighting the treatment interventions and the molecular data from the time of diagnosis. cfDNA, circulating cell-free DNA; SAR, stereotactic ablative radiation.
case_images: PO.19.00013f2.jpg
case_images: PMC7450917_01_PO.19.00013f2.jpg
case_images: f2
case_images: Disease remains in control 6 months later, while the patient continues receiving lorlatinib (Fig 2).